Shareholders of pharma companies Biovail and Valeant voted to approve their merger, and the new company is now called Valeant Pharmaceuticals International. Valeant markets Migranal dihydroergotamine nasal spray in the US, and Biovail had been partnered with Alexza on the development of Staccato loxapine since February 2010. FDA action on the Staccato loxapine NDA is expected next month. The new company is headquartered in Mississauga, Ontario, Canada. Read the company’s press release.
